The information provided on EL7.AI is for educational and informational purposes only and does not constitute financial advice.
The information provided on EL7.AI is for educational and informational purposes only and does not constitute financial advice.
Sign in to access this content
Sign InIn a move designed to reassure investors regarding cash flow sustainability, AbbVie intends to fund its $10.9 billion acquisition of Apogee entirely through debt. According to reports, this strategy aims to keep the company's cash reserves intact without compromising shareholder reward programs. This approach is expected to maintain the stability of the dividend program, leveraging the company's historical record of managing large-scale acquisitions while protecting liquidity.
This step comes as major pharmaceutical companies seek to bolster their biologic drug pipelines; AbbVie is following a path similar to peers like Pfizer and Merck in using leverage to fund growth without cutting payouts. Compared to recent sector deals, AbbVie's choice of debt reflects confidence in its ability to service obligations from future operating cash flows, especially as the company has maintained annual dividend growth for decades, placing it in the "Dividend Aristocrats" category per market data.
Regarding market performance, ABBV stock stood at $254.49 (close July 17, 2026), with daily fluctuations between $254.29 and $260.96. Traders are currently monitoring any updates from credit rating agencies regarding the new debt levels, in addition to watching key US economic data such as the Consumer Price Index (CPI), which recently recorded 3.5% annually, potentially impacting the company's future borrowing costs.